Last reviewed · How we verify
Thero2-01S22
Thero2-01S22's mechanism is unknown.
At a glance
| Generic name | Thero2-01S22 |
|---|---|
| Sponsor | Institut de cancérologie Strasbourg Europe |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
No information is available on the exact mechanism of action of Thero2-01S22.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |